Zofia Piotrowska, MD, of the Massachusetts General Hospital Cancer Center, discusses heterogeneity and variation in resistance mechanisms among EGFR-mutant non–small cell lung cancer patients with at least one postresistance biopsy (Abstract 1).
Maximilian Diehn, MD, PhD, of Stanford School of Medicine, discusses promising clinical applications of circulating tumor DNA in patients with thoracic malignancies: noninvasive detection of resistance mechanisms to targeted agents and treatment response assessment.
Douglas E. Wood, MD, of the University of Washington, discusses the importance of broad access to and education about lung cancer screening—now approved for people at high risk for the disease—and the need for expanded criteria for screening eligibility.
Boris Sepesi, MD, of The University of Texas MD Anderson Cancer Center, discusses immune cells within tumors and the potential role for checkpoint inhibitor therapy in the neoadjuvant setting of locally advanced lung cancer (Abstract 7).
Martin J. Edelman, MD, of Fox Chase Cancer Center, discusses study findings from a phase III study of celecoxib in addition to standard chemotherapy for advanced non–small cell lung cancer with COX-2 overexpression (Abstract 2).
Zhongxing Liao, MD, of The University of Texas MD Anderson Cancer Center, discusses the continued improvement in planning, delivery, and patient selection for proton therapy, which can both reduce radiation exposure and increase tumor dose.
